amlodipine has been researched along with Atherogenesis in 23 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, there are few studies on the regulation and efficacy of atorvastatin combined with amlodipine on Th17/Treg balance in hypertension combined with carotid atherosclerosis." | 9.69 | Effects of amlodipine combined with atorvastatin on Th17/Treg imbalance and vascular microcirculation in hypertensive patients with atherosclerosis: A double-blind, single-center randomized controlled trial. ( Qiu, Y; Yang, G, 2023) |
| "This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function." | 9.15 | The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011) |
| "We examined the effects of 2 calcium channel blockers, benidipine (T-, L-, and N-type) and amlodipine (L- and N-type), on renal, inflammatory, oxidative, and atherosclerosis markers in hypertensive patients with mild chronic kidney disease (CKD)." | 9.14 | Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease. ( Fujiwara, N; Kawagoe, Y; Koide, H; Nakamura, T; Sato, E; Sugaya, T; Ueda, Y; Yamada, S; Yamagishi, S, 2010) |
| "Amlodipine inhibited AngII-induced aortic aneurysms in both the abdominal and ascending regions, and atherosclerosis in hypercholesterolemic mice." | 7.79 | Amlodipine reduces AngII-induced aortic aneurysms and atherosclerosis in hypercholesterolemic mice. ( Balakrishnan, A; Cassis, LA; Charnigo, R; Chen, X; Daugherty, A; Howatt, DA; Moorleghen, JJ; Morris, AJ; Rateri, DL, 2013) |
| "Nifedipine, an L-type calcium channel blocker, protects against the progression of atherosclerosis." | 7.76 | Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. ( Araki, E; Fukuda, K; Ishii, N; Kawada, T; Kim-Mitsuyama, S; Kinoshita, H; Matsumura, T; Miyamura, N; Motoshima, H; Nakao, S; Nishikawa, T; Senokuchi, T; Takeya, M; Tsutsumi, A, 2010) |
| "We conducted a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) to compare metabolic, cardiovascular, and renal outcomes in individuals assigned to initial hypertension treatment with a thiazide-like diuretic (chlorthalidone), a calcium channel blocker (CCB; amlodipine), or an ACE inhibitor (lisinopril) in nondiabetic individuals with or without metabolic syndrome." | 7.74 | Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent ( Baimbridge, C; Barzilay, J; Basile, J; Black, HR; Dart, RA; Davis, B; Marginean, H; Nwachuku, C; Thadani, U; Whelton, P; Wong, ND; Wright, JT, 2008) |
| "We examined whether amlodipine, an L-type calcium channel blocker (CCB), has an inhibitory effect on oxidative stress and inflammatory response, and thereby atherosclerosis, in apolipoprotein E-deficient (ApoEKO) mice." | 7.73 | Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. ( Chen, R; Fukunaga, S; Higaki, J; Horiuchi, M; Ide, A; Iwai, M; Li, Z; Mogi, M; Oshita, A; Yoshii, T, 2006) |
| " However, there are few studies on the regulation and efficacy of atorvastatin combined with amlodipine on Th17/Treg balance in hypertension combined with carotid atherosclerosis." | 5.69 | Effects of amlodipine combined with atorvastatin on Th17/Treg imbalance and vascular microcirculation in hypertensive patients with atherosclerosis: A double-blind, single-center randomized controlled trial. ( Qiu, Y; Yang, G, 2023) |
| "There is lacking evidence that telmisartan can improve insulin resistance in patients on high-intensity statins." | 5.51 | Effects of high-intensity statin combined with telmisartan versus amlodipine on glucose metabolism in hypertensive atherosclerotic cardiovascular disease patients with impaired fasting glucose: A randomized multicenter trial. ( Kang, TS; Kim, BK; Kim, JY; Lee, CJ; Lee, SH; Park, S; Sung, JH, 2022) |
| "Amlodipine is a mixture of two enantiomers, one of which (S- enantiomer) has L-type channel blocking activity, while the other (R+ enantiomer) shows ~1000-fold weaker channel blocking activity than S- enantiomer and has other unknown effects." | 5.48 | Amlodipine Inhibits Vascular Cell Senescence and Protects Against Atherogenesis Through the Mechanism Independent of Calcium Channel Blockade. ( Hayashi, Y; Ikegami, R; Katsuumi, G; Kayamori, H; Minamino, T; Shimizu, I; Suda, M; Wakasugi, T; Yoshida, Y, 2018) |
| "To evaluate whether the direct renin inhibitor, aliskiren, has a more favorable effect compared to amlodipine on atherosclerotic biomarkers in patients with stable coronary artery disease and diabetes currently receiving standard secondary prevention therapy." | 5.17 | Effects of direct renin inhibition on atherosclerotic biomarkers in patients with stable coronary artery disease and type 2 diabetes mellitus. ( Abo-Salem, E; Doctolero, S; Irons, BK; Meyerrose, GE; Seifert, CF; Simoni, JS; Trujillo, A, 2013) |
| "This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function." | 5.15 | The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011) |
| "We examined the effects of 2 calcium channel blockers, benidipine (T-, L-, and N-type) and amlodipine (L- and N-type), on renal, inflammatory, oxidative, and atherosclerosis markers in hypertensive patients with mild chronic kidney disease (CKD)." | 5.14 | Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease. ( Fujiwara, N; Kawagoe, Y; Koide, H; Nakamura, T; Sato, E; Sugaya, T; Ueda, Y; Yamada, S; Yamagishi, S, 2010) |
| "BP control with ramipril or amlodipine could not provide adequate protection for development or progression of atherosclerosis and eccentric type of LVH in nondiabetic HD patients." | 5.14 | Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. ( Akinci, D; Altun, B; Kahraman, S; Ozer, N; Turgan, C; Yilmaz, R, 2010) |
| "Amlodipine inhibited AngII-induced aortic aneurysms in both the abdominal and ascending regions, and atherosclerosis in hypercholesterolemic mice." | 3.79 | Amlodipine reduces AngII-induced aortic aneurysms and atherosclerosis in hypercholesterolemic mice. ( Balakrishnan, A; Cassis, LA; Charnigo, R; Chen, X; Daugherty, A; Howatt, DA; Moorleghen, JJ; Morris, AJ; Rateri, DL, 2013) |
| "Nifedipine, an L-type calcium channel blocker, protects against the progression of atherosclerosis." | 3.76 | Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. ( Araki, E; Fukuda, K; Ishii, N; Kawada, T; Kim-Mitsuyama, S; Kinoshita, H; Matsumura, T; Miyamura, N; Motoshima, H; Nakao, S; Nishikawa, T; Senokuchi, T; Takeya, M; Tsutsumi, A, 2010) |
| "We conducted a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) to compare metabolic, cardiovascular, and renal outcomes in individuals assigned to initial hypertension treatment with a thiazide-like diuretic (chlorthalidone), a calcium channel blocker (CCB; amlodipine), or an ACE inhibitor (lisinopril) in nondiabetic individuals with or without metabolic syndrome." | 3.74 | Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent ( Baimbridge, C; Barzilay, J; Basile, J; Black, HR; Dart, RA; Davis, B; Marginean, H; Nwachuku, C; Thadani, U; Whelton, P; Wong, ND; Wright, JT, 2008) |
| "We investigated the pleiotropic effects of a calcium antagonist (amlodipine) on early atherosclerosis development in the presence and absence of an HMG-CoA-reductase inhibitor (atorvastatin) in apolipoprotein E*3-Leiden/human C-reactive protein (E3L/CRP) transgenic mice." | 3.73 | Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice. ( de Maat, M; Emeis, J; Havekes, L; Jukema, W; Maas, A; Offerman, E; Princen, H; Szalai, A; Trion, A; van der Laarse, A, 2006) |
| "We examined whether amlodipine, an L-type calcium channel blocker (CCB), has an inhibitory effect on oxidative stress and inflammatory response, and thereby atherosclerosis, in apolipoprotein E-deficient (ApoEKO) mice." | 3.73 | Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. ( Chen, R; Fukunaga, S; Higaki, J; Horiuchi, M; Ide, A; Iwai, M; Li, Z; Mogi, M; Oshita, A; Yoshii, T, 2006) |
| "Amlodipine is a classical drug with varied properties extending from control of blood pressure to as an antianginal and anti atherosclerotic agent." | 2.58 | Amlodipine in the Era of New Generation Calcium Channel Blockers. ( Kashyap, R; Langote, A; Tiwaskar, M; Toppo, A, 2018) |
| "Amlodipine is a mixture of two enantiomers, one of which (S- enantiomer) has L-type channel blocking activity, while the other (R+ enantiomer) shows ~1000-fold weaker channel blocking activity than S- enantiomer and has other unknown effects." | 1.48 | Amlodipine Inhibits Vascular Cell Senescence and Protects Against Atherogenesis Through the Mechanism Independent of Calcium Channel Blockade. ( Hayashi, Y; Ikegami, R; Katsuumi, G; Kayamori, H; Minamino, T; Shimizu, I; Suda, M; Wakasugi, T; Yoshida, Y, 2018) |
| "Amlodipine was found to induce TGF-beta synthesis from mononuclear cells with increasing concentrations, while it was found to inhibit TNF-alpha secretion with increasing concentrations." | 1.33 | TGF-beta and TNF-alpha producing effects of losartan and amlodipine on human mononuclear cell culture. ( Dikmen, T; Gul, S; Kaynar, K; Ovali, E; Ulusoy, S; Vanizor, B, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (34.78) | 29.6817 |
| 2010's | 11 (47.83) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, CJ | 1 |
| Sung, JH | 1 |
| Kang, TS | 1 |
| Park, S | 2 |
| Lee, SH | 1 |
| Kim, JY | 1 |
| Kim, BK | 1 |
| Yang, G | 1 |
| Qiu, Y | 1 |
| Lu, Y | 1 |
| Yin, J | 1 |
| Wu, X | 1 |
| Fan, Y | 1 |
| Liu, F | 1 |
| Ivashchuk, Y | 1 |
| Cheung, DWS | 1 |
| Koon, JCM | 1 |
| Wong, PH | 1 |
| Yau, KC | 1 |
| Wat, ECL | 1 |
| Chan, JYW | 1 |
| Lau, VKM | 1 |
| Ko, ECH | 1 |
| Waye, MMY | 1 |
| Fung, KP | 1 |
| Kayamori, H | 1 |
| Shimizu, I | 1 |
| Yoshida, Y | 1 |
| Hayashi, Y | 1 |
| Suda, M | 1 |
| Ikegami, R | 1 |
| Katsuumi, G | 1 |
| Wakasugi, T | 1 |
| Minamino, T | 1 |
| Tiwaskar, M | 1 |
| Langote, A | 1 |
| Kashyap, R | 1 |
| Toppo, A | 1 |
| Athyros, VG | 1 |
| Katsiki, N | 1 |
| Karagiannis, A | 1 |
| Irons, BK | 1 |
| Trujillo, A | 1 |
| Seifert, CF | 1 |
| Simoni, JS | 1 |
| Doctolero, S | 1 |
| Abo-Salem, E | 1 |
| Meyerrose, GE | 1 |
| Chen, X | 1 |
| Rateri, DL | 1 |
| Howatt, DA | 1 |
| Balakrishnan, A | 1 |
| Moorleghen, JJ | 1 |
| Morris, AJ | 1 |
| Charnigo, R | 1 |
| Cassis, LA | 1 |
| Daugherty, A | 1 |
| Kim, JS | 1 |
| Yan, P | 1 |
| Jeffers, BW | 1 |
| Cerezo, C | 1 |
| Nakamura, T | 1 |
| Sato, E | 1 |
| Fujiwara, N | 1 |
| Kawagoe, Y | 1 |
| Ueda, Y | 1 |
| Sugaya, T | 1 |
| Yamagishi, S | 1 |
| Yamada, S | 1 |
| Koide, H | 1 |
| Ishii, N | 1 |
| Matsumura, T | 1 |
| Kinoshita, H | 1 |
| Fukuda, K | 1 |
| Motoshima, H | 1 |
| Senokuchi, T | 1 |
| Nakao, S | 1 |
| Tsutsumi, A | 1 |
| Kim-Mitsuyama, S | 1 |
| Kawada, T | 1 |
| Takeya, M | 1 |
| Miyamura, N | 1 |
| Nishikawa, T | 1 |
| Araki, E | 1 |
| Yilmaz, R | 1 |
| Altun, B | 1 |
| Kahraman, S | 1 |
| Ozer, N | 1 |
| Akinci, D | 1 |
| Turgan, C | 1 |
| Yamamoto, K | 1 |
| Ozaki, H | 1 |
| Takayasu, K | 1 |
| Akehi, N | 1 |
| Fukui, S | 1 |
| Sakai, A | 1 |
| Kodama, M | 1 |
| Shimonagata, T | 1 |
| Kobayashi, K | 1 |
| Ota, M | 1 |
| Horiguchi, Y | 1 |
| Ebisuno, S | 1 |
| Katsube, Y | 1 |
| Yamazaki, T | 1 |
| Ohtsu, H | 1 |
| Hori, M | 1 |
| Kaynar, K | 1 |
| Ulusoy, S | 1 |
| Ovali, E | 1 |
| Vanizor, B | 1 |
| Dikmen, T | 1 |
| Gul, S | 1 |
| Akira, K | 1 |
| Amano, M | 1 |
| Okajima, F | 2 |
| Hashimoto, T | 1 |
| Oikawa, S | 1 |
| Trion, A | 1 |
| de Maat, M | 1 |
| Jukema, W | 1 |
| Maas, A | 1 |
| Offerman, E | 1 |
| Havekes, L | 1 |
| Szalai, A | 1 |
| van der Laarse, A | 1 |
| Princen, H | 1 |
| Emeis, J | 1 |
| Yoshii, T | 1 |
| Iwai, M | 1 |
| Li, Z | 1 |
| Chen, R | 1 |
| Ide, A | 1 |
| Fukunaga, S | 1 |
| Oshita, A | 1 |
| Mogi, M | 1 |
| Higaki, J | 1 |
| Horiuchi, M | 1 |
| Martín-Ventura, JL | 1 |
| Tuñon, J | 1 |
| Duran, MC | 1 |
| Blanco-Colio, LM | 1 |
| Vivanco, F | 1 |
| Egido, J | 1 |
| Doran, DE | 1 |
| Weiss, D | 1 |
| Zhang, Y | 1 |
| Griendling, KK | 1 |
| Taylor, WR | 1 |
| Black, HR | 1 |
| Davis, B | 1 |
| Barzilay, J | 1 |
| Nwachuku, C | 1 |
| Baimbridge, C | 1 |
| Marginean, H | 1 |
| Wright, JT | 1 |
| Basile, J | 1 |
| Wong, ND | 1 |
| Whelton, P | 1 |
| Dart, RA | 1 |
| Thadani, U | 1 |
| Nussberger, J | 1 |
| Aubert, JF | 1 |
| Bouzourene, K | 1 |
| Pellegrin, M | 1 |
| Hayoz, D | 1 |
| Mazzolai, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for amlodipine and Atherogenesis
| Article | Year |
|---|---|
Amlodipine in the Era of New Generation Calcium Channel Blockers.
Topics: Albuminuria; Amlodipine; Atherosclerosis; Calcium Channel Blockers; Diabetes Complications; Diabetic | 2018 |
Vascular protection of dual therapy (atorvastatin-amlodipine) in hypertensive patients.
Topics: Amlodipine; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Calcium Channel Blockers; Drug | 2006 |
8 trials available for amlodipine and Atherogenesis
| Article | Year |
|---|---|
Effects of high-intensity statin combined with telmisartan versus amlodipine on glucose metabolism in hypertensive atherosclerotic cardiovascular disease patients with impaired fasting glucose: A randomized multicenter trial.
Topics: Amlodipine; Atherosclerosis; Cardiovascular Diseases; Fasting; Glucose; Heart Diseases; Humans; Hydr | 2022 |
Effects of amlodipine combined with atorvastatin on Th17/Treg imbalance and vascular microcirculation in hypertensive patients with atherosclerosis: A double-blind, single-center randomized controlled trial.
Topics: Amlodipine; Atherosclerosis; Atorvastatin; Carotid Artery Diseases; Humans; Hypertension; Microcircu | 2023 |
Comparative effects of 2.5mg levamlodipine and 5mg amlodipine on vascular endothelial function and atherosclerosis.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atherosclerosis; Endothelium, Vascular | 2019 |
Effects of direct renin inhibition on atherosclerotic biomarkers in patients with stable coronary artery disease and type 2 diabetes mellitus.
Topics: Aged; Amides; Amlodipine; Atherosclerosis; Biomarkers; Blood Pressure; Coronary Artery Disease; Diab | 2013 |
Effect of inter-individual blood pressure variability on the progression of atherosclerosis in carotid and coronary arteries: a post hoc analysis of the NORMALISE and PREVENT studies.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosi | 2017 |
Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Amlodipine; Atherosclerosis; Biomarkers; Calcium Channel Blocker | 2010 |
Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atherosclerosis; Carotid Arteries; Female; Heart V | 2010 |
The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin II Type 2 Receptor Blockers; Antihyperte | 2011 |
13 other studies available for amlodipine and Atherogenesis
| Article | Year |
|---|---|
[REMODELING OF THE LEFT VENTRICLE, SUBCLINICAL MANIFESTATIONS OF ATHEROSCLEROSIS IN PATIENTS WITH HYPERTONIC DISEASE WITH RHEUMATOID ARTHRITIS BY THE INFLUENCE OF DIFFERENT TREATMENT SCHEMES].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Arthritis, Rheumatoid; Atherosclerosis; Blood Pres | 2021 |
Combination of atorvastatin or hydrochlorothiazide/amlodipine with
Topics: Amlodipine; Atherosclerosis; Atorvastatin; Drugs, Chinese Herbal; Humans; Hydrochlorothiazide; Hyper | 2021 |
Amlodipine Inhibits Vascular Cell Senescence and Protects Against Atherogenesis Through the Mechanism Independent of Calcium Channel Blockade.
Topics: Amlodipine; Animals; Atherosclerosis; Blotting, Western; Calcium Channel Blockers; Calcium Channels; | 2018 |
Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients.
Topics: Age Factors; Amlodipine; Antihypertensive Agents; Atherosclerosis; Cardiovascular Diseases; Choleste | 2013 |
Amlodipine reduces AngII-induced aortic aneurysms and atherosclerosis in hypercholesterolemic mice.
Topics: Amlodipine; Angiotensin II; Animals; Aortic Aneurysm; Atherosclerosis; Hyperlipoproteinemia Type II; | 2013 |
Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice.
Topics: Amlodipine; Animals; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Bin | 2010 |
TGF-beta and TNF-alpha producing effects of losartan and amlodipine on human mononuclear cell culture.
Topics: Amlodipine; Antihypertensive Agents; Atherosclerosis; Cells, Cultured; Humans; Leukocytes, Mononucle | 2005 |
Inhibitory effects of amlodipine and fluvastatin on the deposition of advanced glycation end products in aortic wall of cholesterol and fructose-fed rabbits.
Topics: Amlodipine; Animals; Antioxidants; Aorta; Atherosclerosis; Calcium Channel Blockers; Cholesterol, Di | 2006 |
Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice.
Topics: Amlodipine; Animals; Apolipoprotein E3; Apolipoproteins E; Atherosclerosis; Atorvastatin; Blood Pres | 2006 |
Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions.
Topics: Amlodipine; Animals; Anti-Inflammatory Agents; Antioxidants; Apolipoproteins E; Atherosclerosis; Cal | 2006 |
Differential effects of AT1 receptor and Ca2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Animals; Aorta; Atherosclerosis; Benzimidazoles; Biphe | 2007 |
Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent
Topics: Aged; Amlodipine; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Chlorthalidone; Cohort S | 2008 |
Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
Topics: Amides; Amlodipine; Animals; Antihypertensive Agents; Apolipoproteins E; Atenolol; Atherosclerosis; | 2008 |